Blog Exposure – AstraZeneca’s LYNPARZA(R) Reports Encouraging Results from Phase-III 1st-Line SOLO-1 Trial for Advanced Ovarian Cancer

LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want access to our free research report on AstraZeneca PLC (NYSE: AZN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AZN as the Company’s latest news hit the wire. On June 27, 2018, the Company and Merck & Co., Inc. (NYSE: MRK) together announced encouraging results from the randomized, double-blinded, placebo-controlled, Phase-III SOLO-1 trial assessing LYNPARZA® (olaparib) tablets (300 mg twice daily) in BRCA-mutated (BRCAm) advanced ovarian cancer. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, AstraZeneca most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AZN

SOLO-1 is a Phase-III randomized, double-blinded, placebo-controlled multi-center trial to evaluate the efficacy and safety of LYNPARZA® tablets as a 1st-line maintenance monotherapy compared to placebo, in patients with BRCAm advanced ovarian cancer.

LYNPARZA® Met Primary Endpoint of Progression-Free Survival Compared to Placebo

Women with BRCAm advanced ovarian cancer treated 1st-line with LYNPARZA® maintenance therapy had a statistically-significant and clinically-meaningful improvement in progression-free survival compared to placebo. The safety and tolerability profile of LYNPARZA® was consistent with previous trials. AstraZeneca and Merck plan to initiate discussions with health authorities regarding regulatory submissions.

SOLO-1 Data Reinforce the Importance of Knowing BRCA Status at Diagnosis

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, stated that for the first time, the Company sees a significant and clinically-impactful improvement in progression-free survival in the 1st-line maintenance setting for women with BRCA-mutated ovarian cancer treated with a PARP inhibitor. Bohen added that the SOLO-1 data reinforces the importance of knowing BRCA status at diagnosis, as this may enable women with BRCA-mutated ovarian cancer to receive LYNPARZA® earlier.

PAOLA-1 Trial is testing LYNPARZA® in Combination with Bevacizumab as a Maintenance Treatment in Newly-Diagnosed Advanced Ovarian Cancer

LYNPARZA® is indicated for the maintenance treatment of recurrent ovarian cancer in response to platinum-based chemotherapy regardless of BRCA mutation status, and for the treatment of advanced ovarian cancer patients with a germline BRCA-mutation previously treated with three or more lines of chemotherapy. The ongoing GINECO/ENGOTov25 Phase-III trial, PAOLA-1, sponsored by ENGOT/GCIG, is testing the effect of LYNPARZA® in combination with bevacizumab as a 1st-line maintenance treatment in women with newly-diagnosed advanced ovarian cancer, regardless of their BRCA status. The results for the PAOLA-1 trial are expected in 2019.

About SOLO-1

The trial randomized 391 patients with a deleterious or suspected deleterious BRCA1 or BRCA2 mutation who were in clinical complete or partial response following platinum-based chemotherapy. Eligible patients were randomized (2:1) to receive LYNPARZA® 300 mg tablets twice daily or placebo tablets twice daily. The primary endpoint was progression free survival and secondary key endpoints, including time to second disease progression or death and overall survival.

About LYNPARZA® (Olaparib)

LYNPARZA® was the first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. Specifically, in-vitro studies have shown that LYNPARZA®-induced cytotoxicity may involve the inhibition of PARP-enzymatic activity and an increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death. LYNPARZA® is being tested in a range of DDR-deficient tumor types. LYNPARZA®, which is being jointly developed and commercialized by AstraZeneca and MSD, is approved for advanced ovarian cancer and metastatic breast cancer, and has been used in over 20,000 patients worldwide.

About AstraZeneca PLC

Founded in 1999 and headquartered in Cambridge, Cambridgeshire, AstraZeneca is a global, science-led biopharmaceutical organization that focuses on the discovery, development, and commercialization of prescription medicines. The Company focuses on three main therapy areas, namely: Oncology, Cardiovascular & Metabolic Disease (CVMD), and Respiratory.

Stock Performance Snapshot

June 28, 2018 – At Thursday’s closing bell, AstraZeneca’s stock advanced 1.01%, ending the trading session at $34.90.

Volume traded for the day: 2.88 million shares.

Stock performance in the previous six-month period – up 3.50%; past twelve-month period – up 1.60%; and year-to-date – up 0.58%

After yesterday’s close, AstraZeneca’s market cap was at $89.33 billion.

Price to Earnings (P/E) ratio was at 31.24.

The stock has a dividend yield of 4.01%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers – Major industry. This sector was up 0.4% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

SOURCE: Active-Investors

ReleaseID: 504078